Global Metabolism Drugs Market, by Therapy Type (Enzyme Replacement Therapy, Substrate Reduction Therapy, Small Molecule Drugs, and Others), by Application (Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism Disease, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 7,685.0 Million in 2022 and is expected to exhibit a CAGR of 6.3% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
The market players are focused on expansion of manufacturing facility in order to increase the production capacity which is expected to witness significant growth in the global metabolism drugs market over the forecast period. For instance, on April, 23, 2021, Lonza, a contract development and manufacturing company (CDMO) partner to the biopharmaceutical industry, announced the construction of a new small molecule manufacturing complex at its Visp, Switzerland site. The new manufacturing complex will occupy an overall footprint of approximately 2000 m2 with six levels of manufacturing space. The complex will offer several opportunities for future expansions supporting the small molecules technologies offering, which include drug substance, particle engineering technologies such as spray drying dispersion, and drug product.
Global Metabolism Drugs Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a positive impact on the global adult vaccines market, owing to increasing research and development for metabolism drugs against COVID- 19 infection. For instance, On October 7, 2021, an article published by the nature, a scientific journal stated about the Effect of drug metabolism in the treatment of SARS‑CoV‑2 from an entirely computational perspective which showed the results as Possible candidates for the treatment of COVID-19 include the antiviral drugs Favipiravir, Galidesivir, Nitazoxanide, Remdesivir, Ribavirin, Chloroquine, and Hydroxychloroquine due to their ability for the enzymatic inhibition of SARS-CoV-2 outbreak.
Global Metabolism Drugs Market: Key Developments
On August 6, 2021, Sanofi, a pharmaceutical company announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Nexviazyme (avalglucosidase alfa-ngpt) for the treatment of patients one year of age and older with late-onset Pompe disease, a progressive and debilitating muscle disorder that impairs a person’s ability to move and breathe. Nexviazyme is an enzyme replacement therapy (ERT) designed to specifically target the mannose-6-phosphate (M6P) receptor.
Browse 34 Market Data Tables and 38 Figures spread through 156 Pages and in-depth TOC on “Global Metabolism Drugs Market”- Forecast to 2030, Global Metabolism Drugs Market, Therapy Type (Enzyme Replacement Therapy, Substrate Reduction Therapy, Small Molecule Drugs, and Others), by Application (Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism Disease, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights related to Global Temperature Management Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/metabolism-drugs-market-1955
Moreover, increasing product approval by regulatory authorities is expected to drive the market growth during the forecast period. For instance, according to the data provided by the World Health Organization, on November 2, 2021, GC Pharma, a biopharmaceutical company announced that the European Medicines Agency (EMA) granted orphan drug designation (ODD) to Hunterase ICV (intracerebroventricular, generic name: idursulfase-beta (recombinant)) for the treatment of mucopolysaccharidosis type II (Hunter syndrome) in the European Union.
Key Takeaways of the Global Metabolism Drugs Market:
- The global metabolism drugs market is expected to exhibit a CAGR of 6.3% during the forecast period due to the increasing research and development activities by market players. For instance, on November 22, 2021, Codexis, Inc., an enzyme engineering company announced that two of the Company’s wholly owned Biotherapeutics programs, CDX-6512 for the treatment of homocystinuria (HCU). The enzyme candidates are gastrointestinal (GI)-stable enzymes specifically engineered to be highly resistant to both the acidic conditions of the stomach and to proteases of the upper intestines, to effectively degrade methionine and leucine that is liberated from protein digestion.
- Among Application, the glycogen metabolism disease segment holds a dominant position, owing to increasing research and development for metabolism drugs is expected to drive the growth of market. For instance, on October 19, 2021, Beam Therapeutics Inc., a biotechnology company reported new preclinical data demonstrating the ability of its liver-targeted base editing approach to directly correct R83C, one of the primary disease-causing mutations of glycogen storage disease type Ia (GSDIa).
- Among regions, North America is expected to hold the dominant market for metabolism drugs, owing to research and development activities by market players in the region. For instance, on February 10, 2022, Maze Therapeutics, a company translating genetic insights into new precision medicines announced new preclinical data supporting the advancement of MZE001, which aims to address Pompe disease by reducing pathologic glycogen accumulation through the inhibition of muscle glycogen synthase (GYS1).
- Major players operating in the global metabolism drugs market include Merck & Co., Inc., Novartis AG, Amicus Therapeutics, AstraZeneca Plc, Boehringer Ingelheim, Shire Plc, Sanofi Genzyme, BioMarin Pharmaceutical, Inc., Horizon Pharma Plc, and GlaxoSmithKline Plc.
